NGS-Based Proteomics: Transforming Biomarker Discovery and Precision Medicine
Key Takeaways
Summary
•
•
•
•
What Is NGS-Based Proteomics?
Proteomics is the large-scale study of proteins, which are the functional molecules driving cellular processes and disease biology. While traditional proteomics relied on mass spectrometry or antibody-based assays, NGS-based proteomics leverages next-generation sequencing platforms to quantify proteins indirectly.
By associating protein-binding events with DNA tags, abundance is encoded into nucleic acid sequences and read out through high-throughput sequencing. Key enabling technologies include:
- DNA-barcoded antibody or affinity reagent platforms (e.g., SomaLogic SomaScan, Olink proximity extension assays).
- Phage display and deep mutational scanning.
- Ribosome or mRNA display technologies.
- Single-cell multi-omics integrating RNA-seq with surface proteomics.
- Aptamer-based proteomics.
The Value of NGS-Based Proteomics
The shift toward sequencing-based quantification offers several important advantages for modern proteomics research. One of the most significant benefits is ultra-high multiplexing, which enables thousands of proteins to be measured simultaneously from very small sample volumes. This capability is particularly valuable for plasma biomarker studies where sample availability may be limited. In addition, the use of DNA amplification provides exceptional sensitivity and dynamic range, allowing researchers to detect low-abundance proteins that are often difficult to capture using conventional assay methods.
Sequencing-based approaches also offer strong scalability. As sequencing technologies continue to become more affordable, the cost per analyte decreases even as the size of protein panels expands. Another major advantage is the natural integration of these datasets with genomic and transcriptomic information, supporting more comprehensive and streamlined multi-omics analysis. Finally, digital sequencing readouts improve reproducibility by reducing the inter-laboratory variability that is commonly associated with traditional analog quantification techniques.
Applications
Technological Foundations
NGS-based proteomics builds on major advances in genomics, including the Human Genome Project, next-generation sequencing, high-affinity aptamers, recombinant antibodies, digital PCR and molecular barcoding. Together with systems biology and computational modelling, these technologies have enabled scalable protein quantification and deeper multi-omics integration across modern biomedical research.
Biomarker Discovery
Large-scale plasma proteomics is enabling the identification of protein signatures linked to cardiovascular, neurological, oncological and autoimmune diseases, supporting earlier and more accurate disease detection.
Oncology Applications
Sequencing-based proteomics enhances cancer research through tumour microenvironment profiling, immune checkpoint analysis, MRD monitoring and integration with genomic data to advance precision oncology.
Diagnostic Applications
NGS-based proteomics is advancing clinical diagnostics through multi-protein risk scores, improving prediction in cardiovascular disease, enabling early cancer detection, and supporting neurodegenerative disease diagnosis. These signatures are also helping to stratify patients and monitor disease progression within precision medicine frameworks.
Immunology & Infectious Disease
This approach supports detailed immune profiling, antibody repertoire mapping, vaccine response tracking and autoantibody discovery, playing a key role in understanding infectious diseases including COVID-19.
Drug Discovery & Target Validation
Proteomic insights enable identification of therapeutic targets, monitoring of drug response, detection of off-target effects and improved patient stratification to support more effective drug development.
Future Projections
NGS-based proteomics represents a major shift in protein analysis, leveraging sequencing technologies to deliver scalable, sensitive and highly multiplexed protein quantification. Built on foundational advances such as the Human Genome Project and molecular barcoding, the field is expected to move progressively from research applications into validated clinical tools over the next decade. This transition will be driven by large-scale longitudinal health studies, AI-enabled biomarker discovery from complex datasets and the development of single-cell proteomics to better understand cellular heterogeneity in disease.
By converting protein detection into a sequencing-based readout, the technology enables high-throughput analysis of thousands of proteins from minimal sample volumes. It is already enhancing biomarker discovery across oncology, cardiovascular, neurodegenerative and immune diseases, while supporting precision medicine through improved patient stratification and treatment response prediction. Seamless integration with genomics and transcriptomics further strengthens its role in multi-omics research, and its digital readouts improve both reproducibility and scalability compared to traditional proteomic methods.
Overall, NGS-based proteomics is positioned as a cornerstone of next-generation healthcare, with applications spanning biomarker discovery, drug development and clinical diagnostics.
Published 13 May 2026
References
- L. Gold, et al., Aptamer-based multiplexed proteomic technology for biomarker discovery, PLoS One, 2010.
- V. Emilsson, et al., Co-regulatory networks of human serum proteins link genetics to disease, Science, 2018.
- E. Ferkingstad, et al., Large-scale integration of the plasma proteome with genetics and disease, Nature Genetics, 2021.
- B.B. Sun, et al., Genomic atlas of the human plasma proteome, Nature, 2018.
- E. Assarsson, et al., Homogeneous 96-plex proximity extension assay for protein biomarker detection, PLoS One, 2014.
- J.G. Smith & R.E. Gerszten, Emerging affinity-based proteomic technologies for large-scale plasma profiling in cardiovascular disease, Circulation, 2017.
- M. Mann, et al., Artificial intelligence for proteomics and biomarker discovery, Cell Systems, 2021.
